Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis

Bibliographic Details
Main Authors:	Alexandre Guy, Anicee Danaee, Koralia Paschalaki, Lisa Boureau, Etienne Rivière, Gabriel Etienne, Olivier Mansier, Michael Laffan, Mallika Sekhar, Chloe James
Format:	Article
Language:	English
Published:	Wiley 2020-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000364

Similar Items

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
by: Sophie Allain-Maillet, et al.
Published: (2020-08-01)

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients
by: Fanti Saktini, et al.
Published: (2015-12-01)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
by: Yonal-Hindilerden I, et al.
Published: (2015-06-01)

Analysis of JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms
by: Soumaya Chadi, et al.
Published: (2021-04-01)

A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders
by: Bárbara C. R. Monte-Mór, et al.
Published: (2008-01-01)

Evaluation of JAK2V617F Mutation Prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: B Bahar, et al.
Published: (2009-11-01)

Evaluation of JAK2V617F mutation prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: H Ghafari, et al.
Published: (2009-09-01)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
by: Shirin Ferdowsi, et al.
Published: (2016-04-01)

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
by: Panhong Gou, et al.
Published: (2024-01-01)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
by: İpek Yonal Hindilerden, et al.
Published: (2023-08-01)

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance
by: Saeid Shahrabi, et al.
Published: (2018-10-01)

JAK2 V617F ALLELE BURDEN IN CHRONIC MYELOPROLIFERATIVE DISEASES
by: Matevž Škerget, et al.
Published: (2008-04-01)

Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series
by: Graeme Greenfield, et al.
Published: (2018-12-01)

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
by: Kristin Holl, et al.
Published: (2024-02-01)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
by: W. Novak, et al.
Published: (2022-06-01)

The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
by: Lai Yee Orbell, et al.
Published: (2023-11-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
by: Fani Kalala, et al.
Published: (2012-06-01)

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
by: Kasper Mønsted Pedersen, et al.
Published: (2020-05-01)

Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
by: Christoph Garbers, et al.
Published: (2020-05-01)

Myeloproliferative Neoplasms Associated with Mutation in JAK2V617F and Tyrosine Kinase Inhibitors as Therapeutic Strategy
by: Kaveh Tari, et al.
Published: (2015-04-01)

Evaluation of JAK2V617F mutation patients with non-CML myeloproliferative neoplasms by ARMS-PCR
by: F Nadali, et al.
Published: (2008-12-01)

Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms.
by: Hye-Ran Kim, et al.
Published: (2013-01-01)

JAK2-V617F mutation in patients with myeloproliferative neoplasms: Association with FLT3-ITD mutation
by: Čolović Milica, et al.
Published: (2010-01-01)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
by: Bench, A, et al.
Published: (2013)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations
by: Bench, A, et al.
Published: (2013)

Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report
by: A, Alia Suzana, et al.
Published: (2023)

PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS
by: Xuefei MA, et al.
Published: (2023-08-01)

Coexistence of JAK2V617F and CALR mutation in Tunisian cohort with Philadelphia-negative chronic myeloproliferative neoplasms
by: Hejer Elmahmoudi, et al.
Published: (2023-01-01)

Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms
by: Panhong Gou, et al.
Published: (2022-01-01)

JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
by: Tamotsu Irino, et al.
Published: (2011-01-01)

Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation
by: Bennemann Karla, et al.
Published: (2012-08-01)

Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms
by: Kanwaljeet Singh, et al.
Published: (2018-01-01)

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with <it>JAK2 V617F </it>mutation: a case report
by: Pemmaraju Naveen, et al.
Published: (2012-04-01)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
by: Hilal Hekimoğlu, et al.
Published: (2022-02-01)

P1009: SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION
by: Ailin Zhao, et al.
Published: (2023-08-01)

PB2040: INTERRELATION BETWEEN JAK2 V617F MUTATION AND THE INCIDENCE OF THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
by: D. Nikolova, et al.
Published: (2022-06-01)

Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms
by: Charly Courdy, et al.
Published: (2023-07-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-04-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-06-01)

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
by: Shivam Rai, et al.
Published: (2022-09-01)